ABVC Stock — ABVC Biopharma Inc

ABVC Biopharma Inc (ABVC)

Updated October 16, 2026.

ABVC is a Stock. Its deepest 1-year drawdown was 76.3%.

ABVC BioPharma is a clinical-stage biopharmaceutical company developing drugs and medical devices for unmet medical needs, including treatments for triple negative breast cancer, depression, ADHD, myelodysplastic syndromes, retinal conditions, lung cancer, and pancreatic cancer, with multiple programs in Phase I and Phase II clinical trials. The company does not currently distribute to shareholders. ABVC BioPharma appeals to investors seeking exposure to early-stage biotech development, though clinical-stage companies carry substantial risk of development failure.

ABVC performance

Returns are updating. ABVC's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 76.3%.

ABVC key facts

Asset type

Stock

Asset class

Equity

Inception date

11/10/2004

Distribution frequency

None

Last close

$0.92 (as of 2026-10-16)

Market cap

$24,502,860

Average volume

29201.0

Payment date

05/08/2019

Beta

0.51

Payout ratio

0.0%

EPS

$-0.30

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ABVC risks and drawbacks

The deepest 1-year drawdown on record here is 76.3%.

Who may consider ABVC — and who may not

It is a weaker fit for investors who need monthly cash flow (ABVC does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ABVC

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions